Takamochi K, Nagai K, Yoshida J, Suzuki K, Ohde Y, Nishimura M, Sasaki S, Nishiwaki Y
Division of Thoracic Oncology and the Epidemiology and Biostatistics Division, National Cancer Center Hospital East, Chiba, Japan.
J Thorac Cardiovasc Surg. 2001 Aug;122(2):325-30. doi: 10.1067/mtc.2001.114355.
It is not clear whether lymphadenectomy has therapeutic benefit in non-small cell lung cancer management. To avoid unnecessary lymphadenectomy, we attempted to identify clinical or radiologic predictors of pathologic N0 disease in patients with peripheral adenocarcinoma.
From August 1992 through April 1997, 269 consecutive patients with peripheral adenocarcinoma who underwent major lung resection and systematic lymph node dissection were enrolled in this study. We reviewed their contrast-enhancement computed tomographic scans and recorded the maximum dimension of tumors both on pulmonary (pDmax) and on mediastinal (mDmax) window setting images, the largest dimension perpendicular to the maximum axis on both pulmonary (pDperp) and mediastinal (mDperp) window setting images, and the size of all detectable hilar-mediastinal lymph nodes. We defined a new radiologic parameter, tumor shadow disappearance rate (TDR), which is calculated with the following formula: TDR = 1 - (mDmax x mDperp)/(pDmax x pDperp).
In multivariable analysis a lower serum carcinoembryonic antigen level and a higher tumor shadow disappearance rate were significant predictors of pathologic N0 disease. Lymph node size on computed tomographic scanning was not a significant predictor. Among 59 patients with a normal preoperative carcinoembryonic antigen level and a tumor shadow disappearance rate of 0.8 or more, 58 (98%) patients had pathologic N0 disease, and the other patient had pathologic N1 disease.
Mediastinal lymph node involvement was not found in patients with a normal preoperative serum carcinoembryonic antigen level and a tumor shadow disappearance rate 0.8 or more. The patients who meet these criteria may be successfully managed with major lung resection without systematic mediastinal lymphadenectomy.
在非小细胞肺癌的治疗中,淋巴结清扫术是否具有治疗益处尚不清楚。为避免不必要的淋巴结清扫术,我们试图确定周围型腺癌患者病理N0疾病的临床或影像学预测因素。
从1992年8月至1997年4月,本研究纳入了269例连续接受肺大切除及系统性淋巴结清扫的周围型腺癌患者。我们回顾了他们的增强计算机断层扫描,并记录了肺部(pDmax)和纵隔(mDmax)窗位图像上肿瘤的最大直径、肺部(pDperp)和纵隔(mDperp)窗位图像上垂直于最大轴的最大直径,以及所有可检测到的肺门-纵隔淋巴结的大小。我们定义了一个新的影像学参数,肿瘤阴影消失率(TDR),其计算公式如下:TDR = 1 - (mDmax × mDperp)/(pDmax × pDperp)。
在多变量分析中,较低的血清癌胚抗原水平和较高的肿瘤阴影消失率是病理N0疾病的显著预测因素。计算机断层扫描上的淋巴结大小不是显著预测因素。在59例术前癌胚抗原水平正常且肿瘤阴影消失率为0.8或更高的患者中,58例(98%)患者病理为N0疾病,另一例患者病理为N1疾病。
术前血清癌胚抗原水平正常且肿瘤阴影消失率为0.8或更高的患者未发现纵隔淋巴结受累。符合这些标准的患者可以成功地进行肺大切除,而无需系统性纵隔淋巴结清扫术。